Data refreshed: 2026-03-14 PT from ClinicalTrials.gov
| Metric | Value |
|---|---|
| Total Clinical Trials | 12 |
| Active Trials (Recruiting/Active) | 3 (25%) |
| Phase 1 Trials | 3 |
| Phase 2 Trials | 0 |
| Phase 3 Trials | 0 |
Heat Shock Proteins (HSPs) are molecular chaperones essential for protein folding quality control, aggregate clearance, and cellular proteostasis 1. Dysregulation of HSP function is implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), making HSP modulation a promising therapeutic strategy. [1]
The HSP therapeutic landscape remains in early stages compared to other mechanism areas like amyloid or tau targeting. With only 12 total trials and no late-stage programs, HSP therapeutics represent a significant gap in the neurodegeneration pipeline. This presents both a risk (lack of clinical validation) and an opportunity (first-in-class potential for successful programs).
HSP therapeutics for neurodegeneration face unique challenges:
Despite these challenges, the fundamental biology remains compelling. Protein misfolding and aggregation are central to neurodegeneration, and enhancing the cell's natural chaperone capacity offers a disease-modifying approach.
HSP90 (Heat Shock Protein 90) is a key chaperone involved in folding and stabilization of over 200 client proteins, including many implicated in neurodegeneration 1. In AD, HSP90 clients include tau, APP-processing enzymes, and kinases 2. In PD, α-synuclein aggregation is regulated by HSP90 2. [2]
HSP70 (including HSPA1A, HSPA8, HSPA4) promotes aggregate clearance and prevents misfolding 3. Induction of HSP70 via heat shock or pharmacological agents enhances clearance of toxic protein species. [3]
The small HSP family (HSPB1/Hsp27, HSPB5/α-crystallin, HSPB6/Hsp20) functions as ATP-independent chaperones that prevent aggregation and can cooperate with HSP70 for clearance 1. [4]
| Drug/Program | Target | Company | Development Stage | Indication |
|---|---|---|---|---|
| 17-AAG (Tanespimycin) | HSP90 | NCI/Various | Preclinical/Phase I (discontinued) | AD, Cancer |
| 17-DMAG (Alvespimycin) | HSP90 | AstraZeneca | Phase I (discontinued) | Various |
| PU-H71 | HSP90 | Samus Therapeutics | Preclinical | AD, PD |
| Geldanamycin derivatives | HSP90 | Various | Preclinical | Neuroprotection |
| BGP-15 | HSP90 co-chaperone | N/A | Preclinical | ALS, PD |
As of 2026, no HSP-targeted therapeutics have reached late-stage clinical trials for neurodegeneration. Historical trials focused primarily on oncology rather than CNS indications 4.
The HSP space represents a compelling investment opportunity given:
Heat shock protein therapeutics for neurodegeneration remain in early developmental stages with significant untapped potential. While no late-stage trials exist, the fundamental role of HSPs in protein quality control makes this an attractive area for future investment. Key success factors will include: